Technical Analysis for CU6 - Clarity Pharmaceuticals Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Boomer Buy Setup | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | -0.76% | |
| Inside Day | Range Contraction | -0.76% | |
| Wide Bands | Range Expansion | -0.76% | |
| Gapped Up | Strength | -0.76% | |
| Overbought Stochastic | Strength | -0.76% | |
| Calm After Storm | Range Contraction | 1.03% | |
| New 52 Week High | Strength | 1.03% |
| Alert | Time |
|---|---|
| Down 1% | about 12 hours ago |
| Up 2% | about 12 hours ago |
| Up 1% | about 12 hours ago |
| Possible Inside Day | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product is SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Imaging Clinical Medicine Cancers Medicinal Radiochemistry Prostate Cancer Radiopharmaceuticals Treatment Of Cancer Personalized Medicine
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.12 |
| 52 Week Low | 0.675 |
| Average Volume | 899,534 |
| 200-Day Moving Average | 1.860 |
| 50-Day Moving Average | 2.933 |
| 20-Day Moving Average | 3.172 |
| 10-Day Moving Average | 3.692 |
| Average True Range | 0.182 |
| RSI (14) | 75.37 |
| ADX | 41.05 |
| +DI | 46.731 |
| -DI | 7.285 |
| Chandelier Exit (Long, 3 ATRs) | 3.574 |
| Chandelier Exit (Short, 3 ATRs) | 3.046 |
| Upper Bollinger Bands | 4.303 |
| Lower Bollinger Band | 2.040 |
| Percent B (%b) | 0.84 |
| BandWidth | 71.342 |
| MACD Line | 0.332 |
| MACD Signal Line | 0.233 |
| MACD Histogram | 0.0986 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.135 | ||||
| Resistance 3 (R3) | 4.153 | 4.107 | 4.103 | ||
| Resistance 2 (R2) | 4.107 | 4.057 | 4.098 | 4.092 | |
| Resistance 1 (R1) | 4.023 | 4.026 | 4.000 | 4.005 | 4.081 |
| Pivot Point | 3.977 | 3.977 | 3.965 | 3.968 | 3.977 |
| Support 1 (S1) | 3.893 | 3.927 | 3.870 | 3.875 | 3.799 |
| Support 2 (S2) | 3.847 | 3.896 | 3.838 | 3.788 | |
| Support 3 (S3) | 3.763 | 3.847 | 3.778 | ||
| Support 4 (S4) | 3.745 |
